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Abstract 1 
Bombinin and bombinin H are two antimicrobial peptide (AMP) families initially discovered from the 2 
skin secretion of Bombina that share the same biosynthetic precursor-encoding cDNAs, but have 3 
different structures and physicochemical properties. Insight into their possible existing relationship 4 
lead us to perform the combination investigations into their anti-infectious activities. In this work, we 5 
report the molecular cloning and functional characterisation of two novel AMPs belonging to 6 
bombinin and bombinin H families from secretions of Bombina orientalis. Their mature peptides 7 
(BHL-bombinin and bombinin HL), coded by single open-reading frame (ORF), were chemically 8 
synthesised along with an analogue peptide that replaced L-leucine with D-leucine from the 2nd 9 
position of the N-terminus (bombinin HD). Circular dichroism analysis revealed that all of them 10 
displayed well-defined α-helical structures in membrane mimicking environments. Furthermore, 11 
BHL-bombinin displayed broad-spectrum bactericidal activities on a wide range of micro-organisms, 12 
while bombinin H only exhibited a mildly bacteriostatic effect on the Gram-positive bacteria 13 
Staphylococcus aureus. The combination potency of BHL-bombinin with either bombinin HL or 14 
bombinin HD showed the synergistic inhibition activities against S. aureus (FICI 0.375). A 15 
synergistic effect has also been observed between bombinin H and ampicillin, which was further 16 
systematically evaluated and confirmed by in vitro time-killing investigations. Haemolytic and 17 
cytotoxic examinations exhibited a highly synergistic selectivity and low cytotoxicity on mammalian 18 
cells of these three peptides. Taken together, the discovery of the potent synergistic effect of AMPs in 19 
a single biosynthetic precursor with superior functional selectivity provides a promising strategy to 20 
combat multidrug-resistant pathogens in clinical therapy. 21 
Keyword: peptide; skin secretion; antimicrobial; synergism; selectivity 22 
 23 
1. Introduction 24 
Bombinin, one of the typical cationic AMPs, was firstly isolated from the skin secretion of the 25 
yellow-bellied toad B. variegata [1]. The nucleotide sequence analysis of bombinin-related peptides 26 
prompted the existence of a class of structurally differentiated peptides, which were named as 27 
bombinin H [2,3]. Importantly, the presence of a subtle and inconspicuous single D-amino acid (D-28 
alloisoleucine or D-leucine) at the second position from N-terminus of bombinin H, as a consequence 29 
of post-translational modification, was observed. This type of modification may contribute to the 30 
versatile antimicrobial mechanisms of frog skin peptides, and may be beneficial to the prevention of 31 
bacterial resistance [4-6]. However, since the initial discovery of bombinin, bombinin H and D-32 
isoform bombinin H, research have been focused on the study of the individual peptide’s 33 
antimicrobial property, instead of their synergistic potencies. Combined effects of bombinin peptides 34 
with conventional antibiotics, and their antimicrobial selectivity towards pathogens have very rarely 35 
been reported [7].  36 
Here, we report the structural and functional characterisation of two novel, linear cationic α-helical 37 
AMPs, initially identified in a single ORF from the skin secretion of Bombina orientalis. These 38 
peptides belong to the bombinin and bombinin H families. The potent synergistic relationship of the 39 
novel bombinin and bombinin H peptides highlights the significance of combinational utility of AMPs 40 
in the treatment of infections caused by drug-resistant bacteria, this continues to provide researchers 41 
with novel approaches for prospective innovation in clinical studies. 42 
 43 
2. Materials and Methods 44 
2.1 Specimen preparation and secretion harvesting 45 
Specimens of the oriental fire-bellied toad B. orientalis were obtained from a commercial supplier and 46 
raised in a specially designed vivarium until mature, over a period of 4 months. The skin secretions 47 
were collected and lyophilised as previously described [8]. Sampling of skin secretion was performed 48 
by Mei Zhou under UK Animal (Scientific Procedures) Act 1986, project license PPL 2694, issued by 49 
the Department of Health, Social Services and Public Safety, Northern Ireland. Procedures had been 50 
vetted by the IACUC of Queen’s University, Belfast, and approved on 1 March 2011. 51 
2.2 Molecular cloning of novel bombinin and bombinin H precursor-encoding cDNA from the 52 
skin secretion-derived cDNA library 53 
A five-mg lyophilised secretion of B. orientalis was dissolved in 1 ml of mRNA protection buffer, the 54 
polyadenylated mRNA was obtained by using magnetic oligo-dT beads following the instructions of 55 
the manufacturer (Dynal Biotech, Wirral, UK), and subsequently reverse-transcribed. The cDNA was 56 
subjected to 3’-RACE PCR procedure to obtain the full-length prepro-bombinin and prepro-bombinin 57 
H nucleotide sequence using a SMART-RACE kit (Clontech, Oxford, UK) as described by the 58 
manufacturer. For 3′ RACE reaction, a nested universal primer (NUP) (supplied with the kit) and a 59 
degenerate sense primer were designed and performed as previously reported [9,10]. The 3′-RACE 60 
reactions were performed as previous description [11]. 61 
2.3 Identification and structural analysis of deduced mature peptides in the skin secretions  62 
Another 5 mg of lyophilised secretion were dissolved in 1.0 ml of 0.05/99.95 (v/v) trifluoroacetic acid 63 
(TFA)/water and clarified by centrifugation. The rp-HPLC system was fitted with an analytical 64 
column (Phenomenex C-5, 0.46 × 25 cm and pheomenex C-18, 250×10mm), eluting with a linear 65 
gradient formed from trifluoroacetic acid (TFA) / dd water (0.05/99.95, v/v) to TFA / dd water / 66 
Acetonitrile) (0.05/19.95/80.0, v/v/v) in 240 min at 1 ml/min. The fractions were collected 67 
automatically at minute intervals and effluent absorbance was continuously monitored at λ 214 nm 68 
and λ 280 nm. Each reverse phase HPLC fraction was analysed with matrix-assisted, laser 69 
desorption/ionization, time-of-flight mass spectrometry (MALDI-TOF MS) on a linear time-of-flight 70 
Voyager DE mass spectrometer (Perseptive Biosystems, MA, USA) in positive detection mode using 71 
α-cyano-4-hydroxycinnamic acid as the matrix. Fractions containing peptides with molecular masses 72 
coincident with predicted mature peptides from ‘shotgun’ cloning were infused into the LCQ FleetTM 73 
ion-trap electrospray mass spectrometer for analysis (Thermo Quest, San Jose, CA, USA).  74 
2.4 Peptides synthesis and purification  75 
The two-novel identified bombinin peptides and one single residue D-isomer analogue were 76 
synthesised by Tribute® Peptide Synthesizer (Protein Technologies, Inc., Tucson, USA) with solid-77 
phase Fmoc chemistry methodology and amide resin. Their molecular masses were analysed and 78 
confirmed by MALDI-TOF. Then, synthetic replicates were purified with rp-HPLC to obtain high-79 
purity of synthetic peptides. 80 
2.5 Circular dichroism (CD) spectroscopy 81 
CD spectra between 190 nm and 250 nm were performed on a Jasco J-815 CD spectrometer (Jasco, 82 
Essex, UK). The machine units of millidegrees ellipticity were converted to mean residue molar 83 
ellipticity using the following equation (n: the number of peptide bonds; Ellipticity is the raw data 84 
from the instrument): 85 
θ (deg.cm2.dmol−1) = Ellipticity (mdeg)*106 / Pathlength (mm)*[Peptide] (µM)*n 86 
The spectra were recorded at 100 nm/min in ammonium acetate (10 mM) buffer or TFE (50%) 87 
solution. CD measurements were performed at 20 °C with 1 mm path length cuvette. An average of 88 
three scans were collected and automated analysed for each peptide. The final predicted percentage of 89 
secondary structure was calculated using the K2D3 CD spectra web server [12]. 90 
2.6 Antimicrobial activity and minimal biofilm eradication concentration (MBEC) assays 91 
The minimal inhibitory concentrations (MICs) of the synthetic replicates of the AMPs were 92 
determined using quality control strains, the Gram-positive bacterium, Staphylococcus aureus (NCTC 93 
10788), the Gram-negative bacteria Escherichia coli (NCTC 10418) and Pseudomonas aeruginosa 94 
(ATCC 27853), the yeast Candida albicans (NCPF 1467), and MRSA (Methicillin-resistant 95 
Staphylococcus aureus) (ATCC 12493). The reference strains of the microorganisms were initially 96 
incubated in Mueller-Hinton Broth (MHB) for 16–20 h, then the bacterial cultures were diluted to 97 
obtain 1×106 cfu/ml for the bacterial and the yeast culture to 5×105 cfu/ml. The samples were added to 98 
to obtain final concentrations from 1 to 512 mg/l. After 24 h incubation, the OD of each well was 99 
measured at 550 nm. The MIC value was measured as the minimal concentration of peptide with an 100 
OD identical with that of the negative controls [13]. Upon achieved the data from MIC assays, 10 µl 101 
of the medium from each well was taken and inoculated onto Mueller-Hinton agar (MHA) plates. 102 
After 24 h incubation, the minimum bactericidal concentrations (MBCs) and the minimum fungicidal 103 
concentration (MFC) were obtained, which were defined as the lowest concentration of peptide from 104 
which no colonies could be subsequently grown. 105 
The MBECs of the synthetic peptides were determined against Staphylococcus aureus and performed 106 
following a standard method as shown in manufacturer’s instruction (Innovotech, UK). The MBECTM 107 
P&G assay plate with specialised peg architecture that is designed for the formation of biofilm was 108 
used for anti-biofilm susceptibility tests. The procedure of inoculate and subculture were performed as 109 
described before. The inoculum plate was prepared by transferring 200 µl inoculum to the 96-well 110 
plate and kept in a 150-rpm moist orbital incubator for 72 h at 37 °C. After which, the lid with pegs of 111 
the inoculum plate was rinsed by PBS twice, seven replicates of a serial of two-fold diluted peptides 112 
(1–512 mg/l) along with the positive/negative controls were added to corresponding wells. After 113 
incubation at 37 °C for 24 h, the recovery plate was prepared by adding 200 μl recovery medium 114 
(MHB/neutralising agents 20/0.5 (v/v)) into each well. The lid from the inoculum plate was rinsed and 115 
the placed to the recovery plate. After sonication for 30 min, the recovery plate was measured at 550 116 
nm. The minimal biofilm eradication concentration was determined as the lowest concentration with 117 
no microbiology growth was detected. Melittin (Sigma-Aldrich, UK), firstly isolated from honeybee 118 
(Apis mellifera) venom, was taken as positive controls in comparison [14,15]. Both antimicrobial and 119 
biofilm eradication assays were independently performed three times. 120 
2.7 Kinetic time-killing assays  121 
The kinetic time-killing assays were performed with different concentrations of peptides alone or with 122 
another checkerboard titration predicted synergistic agents. The concentration series of peptides alone 123 
or with the synergistic counterpart were added to 1.5 ml micro-centrifuge tubes, which were then 124 
inoculated with a log phase culture of the test organism as described in the previous section. During 125 
the incubation, 50 μl sample of each tube was removed from culture tubes at 0, 5, 10, 20, 30, 60 and 126 
120 min intervals for single peptides or 0, 0.5, 1, 3, 6, and 24 h intervals for synergistic pairs. After 127 
diluted serially with PBS, 50 μl of diluted samples were inoculated on MHA plates and incubated at 128 
37 °C for 24 h for colony counts. The synergistic effect was defined as equal or higher to 2 - log10 - 129 
CFU/ml decrease in bacterial counts compared to the effect of the most active single constituent [16]. 130 
Curves were constructed by plotting the log10 of CFU/ml against time. 131 
2.8 Haemolysis assay 132 
Defibrinated horse erythrocytes (TCS Biosciences Ltd, Buckingham, UK) were prepared to produce a 133 
4% (v/v) suspension of red blood cells in PBS by repeated washings with sterile PBS. A range of 134 
concentrations of synthetic peptides (1 to 512 mg/l) were incubated with red blood cell suspension 135 
samples (200 µl) at 37 °C for 120 min. After incubation, the suspensions of each sample were 136 
centrifuged to obtain the final lysis of red blood cells. OD measurements of supernatants were 137 
recorded at 550 nm. Negative controls were prepared by a 2% (v/v) suspension with PBS in equal 138 
volumes (0% haemolysis), while the positive controls employed consisting a 2% (v/v) suspension 139 
with 2% (v/v) of the non-ionic detergent, Triton X-100 (Sigma–Aldrich, UK) in PBS. HC50 was 140 
defined as the peptide concentration that caused 50 % haemolysis. 141 
2.9 Cytotoxicity testing 142 
The cytotoxicity of synthetic peptides on mammalian cells was examined using human microvessel 143 
endothelial cell (HMEC-1), which were cultured with MCDB 131 medium (Gibco, UK) 144 
supplemented with 10% FBS, 10 mM L-Glutamine, 10 ng/ml EGF and 1% penicillin streptomycin. 145 
5^103 cells/well were seeded into 96-well plates. After 24 h incubation at 37 °C with 5% CO2, 12 h 146 
serum-free starvation was performed, peptides with 10-9–10-4 M concentrations were added for 24 h 147 
treatment prior to 10 µl MTT (5 mg/ml PBS) incubation for 4 h, the grow medium was removed 148 
followed by adding 100 µl of DMSO to dissolve the formazan crystals. The absorbance was measured 149 
at 570 nm. Data from this study were analysed by t-test using GraphPad Prism (version 5.01). A p 150 
value less than 0.05 was considered a significant difference. Negative and positive control treatments 151 
were carried out with culture medium and 1% Triton X-100, respectively. Data from this study were 152 
analysed by one-way ANOVA with Bonferroni’s post-test. 153 
2.10 Evaluation of combination effects of antimicrobial peptides  154 
A two-dimensional checkerboard with 2-fold dilutions of each AMP was used for examining the 155 
combination effects with S. aureus. The dissolved samples of each peptide or antibiotic agent were 156 
diluted from 4×MIC to 1/16 ×MIC. The series of component A were added along the row of a 96-well 157 
plate, while the columns were filled with the diluted component B. Growth control wells containing 158 
only micro-organism medium and sterility control wells with only MHB medium were included. After 159 
the addition of a log-phase bacterial inoculum of 1×106 cfu/ml, plates were incubated at 37 °C for 24 h 160 
and then measured at λ 550 nm. The combination effects were examined by calculating the fractional 161 
inhibitory concentration index (FICI) of each combination as follows: 162 
 163 
After the combination ratio of the two tested compounds was confirmed, lower concentration pairs 164 
were selected to determine the FICI with more accuracy. The profile of the combination was 165 
interpreted as synergistic for FICI≤0.5, additive for 0.5<FICI≤4.0, and antagonistic for FICI˃4.0  166 
[17,18].  167 
For assessing the synergetic activity of bombinin and bombinin H against the growth of mammalian 168 
cell lines, both CalcuSyn software [19] and Jin’s formula [20] were employed. Combination index (CI) 169 
plots were generated by using CalcuSyn software. A value of CI < 1 represents synergy. The 170 
following formula in Jin’s formula was used: Q=Ea+b (Ea+Eb-Ea×Eb). Q is the combination index; 171 
Ea+b represents the cell proliferative inhibition rate of two AMPs; Ea and Eb represents the cell 172 
proliferative inhibition rate for individual peptide. After calculation, the results Q > 1.15 indicates 173 
synergy, and 0.85 < Q < 1.15 indicates an additive effect [19]. 174 
 175 
3. Results 176 
3.1 Molecular cloning of skin secretion precursor cDNA encoding bombinin and bombinin H 177 
The full-length biosynthetic precursor-encoding cDNAs were cloned from the skin secretion-derived 178 
cDNA libraries of Bombina orientalis. The nucleotide of full ORF of the cloned precursor transcripts 179 
and its translated sequences are shown in Figure 1, which contains 139 residues and encodes a novel 180 
bombinin (BHL-bombinin) and a novel bombinin H (bombinin HL). The data of the novel AMPs has 181 
been deposited in Genbank Nucleotide Sequence Database with the accession code LT615078. 182 
The sequences of two novel AMPs were subjected to online BLAST program analysis with the NCBI 183 
on-line portal. The resulting typical primary structures were compared in Figure 2. The BHL-184 
bombinin and bombinin HL, which exhibited as tandem mature peptides in biosynthetic precursor in 185 
Figure 1, revealed 96% and 82% sequence identity respectively, with other bombinins identified from 186 
Bombinatoridae. The main sequence difference was indicated in the last two or three residues in the 187 
C-terminus, where BHL-bombinin is -Ala-Asn- loss and bombinin HL is truncated of -Lys-Lys-Ile- 188 
with a typical Valine residue at 12th position from N-terminus (Figure 2). 189 
3.2 Identification and structure characterisation of novel bombinin and bombinin H by rp-190 
HPLC and MS/MS fragmentation  191 
HPLC fractions with molecular masses coincident with predicted from molecular cloning for BHL-192 
bombinin and bombinin HL were identified (Figure 3) following detected by the ion trap of the LCQ 193 
Fleet mass spectrometer with further tested by MS/MS fragmentation sequencing of doubly-charged 194 
ions derived from frog skin secretions (Figure 4 and 5). 195 
3.3 Circular dichroism (CD) spectra and bioinformatic analysis 196 
The secondary structures of synthetic replicates of AMPs were investigated in 10 mM of ammonium 197 
acetate (pH 7.0, mimicking aqueous environment) and 50% trifluoroethanol (TFE, mimicking the 198 
hydrophobic environment of the microbial membrane) by CD spectroscopy. As shown in Figure S2, 199 
all the peptides displayed random coil conformations in the aqueous environment. However, the 200 
spectrums of peptides were characteristic of α-helix conformations in the presence of 50% TFE, as 201 
indicated by the presence of double negative dichroic bands at approximately 208 and 222 nm. The 202 
web server K2D3 calculation revealed that the helical content for BHL-bombinin is 87.59%, and for 203 
bombinin HD and bombinin HL are 77.73 % in 50 % TFE solution.  204 
The physiochemical parameters of novel AMPs are listed in Table 1, which not only provides 205 
evidence of the possible interactions between peptides and bacterial membrane but also gives more 206 
information on their synergistic mechanisms. The molecular masses of synthetic peptides were 207 
determined by MALDI-TOF (Figure S1). Physiochemical parameters including charge, hydrophobic 208 
moment and hydrophobicity were determined using the Heliquest server [21]. The hydrophobic 209 
moment (µH) was determined by Eisenberg’s scale with a full window in Heliquest server. BHL-210 
bombinin elicits higher cationic but much less hydrophobic properties than bombinin HL, which 211 
exhibit a highly structural and physiochemical differences between the two co-encoded AMPs. These 212 
findings suggest that these two peptides may possess distinguishing roles in the interaction with 213 
micro-organisms and exhibit potent antibacterial activities synergistically. 214 
3.4 Antimicrobial and haemolytic activities  215 
The antimicrobial effects of synthetic AMPs on the growth of the tested microorganisms, and the 216 
biofilm eradication effects on S. aureus are illustrated in table 2. The BHL-bombinin exhibited 217 
stronger antimicrobial activities on Gram-positive bacteria (MIC/MBC: 4mg/l/16mg/l) and yeast 218 
(MIC/MBC: 4mg/l/16mg/l) than Gram-negative bacteria (MIC/MBC: 16-64mg/l/64-128mg/l). In 219 
addition, BHL-bombinin was found to possess a relatively low level of haemolytic activity (0–12.6%) 220 
at the MIC determined against S. aureus and C. albicans (Figure S3). Interestingly, BHL-bombinin 221 
displayed potent inhibitory effects (MIC: 4-16mg/l) towards MRSA and biofilm. By contrast, the MIC 222 
values for bombinin HL and bombinin HD against S. aureus were 256mg/l and 128mg/l respectively 223 
with undetected MBC, which were significantly less effective compared to BHL-bombinin. The 224 
selectivity indices (SIs), which represent the degree of antibacterial selectivity, are showed in Table 2, 225 
higher SI value reflecting a better selectivity towards microbial over mammalian membranes [22]. As 226 
indicated, the BHL-bombinin had a higher SI compared to bombinin HL and bombinin HD, which is 227 
in agreement with previous studies that high level of hydrophobicity may decrease the antimicrobial 228 
selectivity of α-helical peptides [23]. Additionally, compared with the melittin peptide, all the AMPs 229 
investigated in this study exhibited 32 to 128 times higher SI values, which emphasises that 230 
amphibian-derived AMPs are potential research targets for therapeutic alternatives to current 231 
antibiotics. The time-killing curves demonstrated the faster cell-killing effects of BHL-bombinin 232 
compared with the ampicillin, while the kill rates of bombinin HL and bombinin HD were relatively 233 
low (Figure S4). 234 
The combined administration of BHL-bombinin with either bombinin HL or bombinin HD revealed a 235 
synergistic antimicrobial effect against S. aureus (FICI 0.375). In addition, BHL-bombinin showed 236 
additive property with classic antibiotics ampicillin (FICI 0.75), while the novel bombinin H, either 237 
D- or L-amino isoforms, displayed synergistic activities with β-lactam and ampicillin (FICI 0.5). The 238 
synergistic effects were further confirmed by the outcomes of time-killing assays. Figure 6 (a) (b) 239 
exhibits that the isolated S. aureus had a 6.16(±0.76) log10 decrease in cfu/ml at 24 h when incubated 240 
with BHL-bombinin (0.75 mg/l) and bombinin HL (48 mg/l), compared to the single peptide effect. 241 
The time-killing value was 5.83(±0.67) log10 for combined effects of BHL-bombinin (0.75mg/l) and 242 
bombinin HD (24 mg/l). The synergistic effects were also observed when co-administrated bombinin 243 
HL (64 mg/l) with ampicillin (0.016 mg/l), or bombinin HD (32 mg/l) with ampicillin (0.016 mg/l), 244 
which demonstrated a 7.51 (±0.97) log10 and 6.57 (±0.77) log10 decrease in CFU/ml at 24 h 245 
respectively. 246 
3.5 Cytotoxicity assessment of novel bombinin, bombinin H and their synergistic effect on 247 
HMECs (human microvessel endothelial cells) 248 
The anti-proliferative effect data obtained from MTT cell viability assays of each peptide on HMEC-1 249 
cells are represented in Figure 7(a)(b), and their IC50 values are calculated. All the AMPs tested in 250 
this study exhibited low cytotoxicity with cell viabilities exceeding 90% up to the concentration 10-5M 251 
against HMEC-1. For BHL-bombinin, at MIC concentrations (1.6–26.2 µM), 83.5–100.0% HMEC-1 252 
cells remained viable. For bombinin HL and bombinin HD, they displayed relatively lower selectivity 253 
and higher cytotoxicity on HMEC-1 cells compared with BHL-bombinin. To identify the possible 254 
synergistic cytotoxicity between BHL-Bombinin and bombinin HL or bombinin HD, the cells were 255 
cultured with combinations of these two peptides at different doses but in a constant ratio (BHL-256 
bombinin to bombinin HL or bombinin HD: 5 μM to 10 μM, 10 μM to 20 μM, and 20 μM to 40 μM, 257 
respectively) for 24 h. The combination of 20 μM BHL-bombinin with 40 μM bombinin HL inhibited 258 
cell growth of 52.21%, compared with mono-administration of BHL-bombinin (43.93%) or bombinin 259 
HL (9.63%), indicating an additive effect (CI = 1.03; Q = 1.06). The values for combination of BHL-260 
bombinin and bombinin HD were CI = 0.98; Q = 1.10. The results revealed that the synergistic 261 
relationship was abolished with 0.85 < Q < 1.15 and CI ≥ 1 with regards to their cytotoxicity on 262 
normal mammalian cells. 263 
 264 
4. Discussion 265 
Different from the well-studied bioactive peptides from the amphibian Pipidae, Hylidae, Ranidae, and 266 
Pseudidae families, skin secretions from Bombina species, remain to be investigated fully and may 267 
yield valuable promotion for drug development. The best-known constituent identified from Bombina 268 
skin secretions is bombesin, which led to the subsequent identification of the mammalian homologues, 269 
gastrin-releasing peptide (GRP) and neuromedin B (NMB) as neuropeptides [24]. Among all the 270 
molecules secreted from Bombina species, no counterparts of the novel BHL-bombinin and bombinin 271 
HL, which are encoded by single coding region precursor, have been identified in other amphibian 272 
genera or in mammals [25].  273 
The present study describes the molecular cloning, primary structure identification, chemical 274 
synthesis, and bioactive examinations of two tandem-coded novel bombinin peptides. Since the D-275 
isomer exists in some of the bombinin H-type molecular at the 2nd position of their sequences, the 276 
analogue bombinin HD was designed by substituting the L-leucine at such position. CD studies 277 
revealed that the helical content of BHL-bombinin was only approximately 10% higher than bombinin 278 
HL and bombinin HD, while the hydrophobicity of BHL-bombinin is significant lower than that 279 
bombinin HL and bombinin HD. Therefore, all the tested AMPs in this study were found to adapt an 280 
amphipathic α-helical conformation in a membrane mimetic environment, a feature that is essential 281 
for allowing AMPs to exert their bioactivities [26]. However, due to the diversities of their primary 282 
structures and physiochemical parameters, the functional mechanisms that they employed can be 283 
significantly different.  284 
Synthetic BHL-bombinin were found to possess potent antimicrobial activities against S. aureus and 285 
C. albicans, but relatively lower activity against E. coli and P. aeruginosa. The MBCs for all the four 286 
tested micro-organisms were approximately equal to or over 4-fold of their respect MICs. Clinically, 287 
the formation of biofilm and conventional antibiotic resistant strain MRSA are two major causes of 288 
antibiotic crisis. BHL-bombinin showed potent effects for eliminating S. aureus biofilm and inhibiting 289 
the growth of isolated MRSA. However, the MICs observed for wild-type bombinin HL and analogue 290 
bombinin HD, were moderately effective against S. aureus with undetected MBC. The antimicrobial 291 
properties of the peptides reported in this study were further compared against melittin, which is a 292 
well-studied bee venom derived AMP [15]. BHL-bombinin exhibited similar antimicrobial activity to 293 
melittin, but weaker haemolytic activity, which indicates a better selectivity. Both bombinin H 294 
peptides possessed mild antibacterial property but higher selective antimicrobial activity compared to 295 
melittin. Following on from this, the BHL-bombinin and bombinin HL are tandem-encoded in single 296 
ORF, which prompt us to speculate that their combination effect might be vital for frogs to survive in 297 
pathogens-rich environments. Of note, the combination effect between novel components and 298 
conventional antibiotics has also been proven as a promising solution to amplify the potency of 299 
antibiotics, a good example is Co-amoxiclav, which enormously enhances the Amoxicillin potency 300 
after combined use of clavulanic acid [27]. As expected, the combination interaction of BHL-301 
bombinin with either bombinin HL or bombinin HD showed synergistic inhibition activities against 302 
Staphylococcus aureus (FICI 0.375). Moreover, BHL-bombinin showed additive effect with classic 303 
antibiotics ampicillin (FICI 0.75), while the bombinin HL and HD, displayed synergistic activities 304 
with β-lactam, ampicillin (FICI 0.5). The results were further confirmed by time-killing assays, that 305 
the BHL-bombinin exerted higher bactericidal rate compared with ampicillin. However, the killing 306 
rates for bombinin HL and bombinin HD were diminished. The mechanism of the positive outcomes 307 
between peptides and conventional antibiotics (ampicillin in this study) appears to be complex. The 308 
fractional inhibitory concentration (FIC) index as a measure of synergy employed in this study is the 309 
best known and a very basic method for evaluating the inhibitory effects of paired agents comparing 310 
the sum of their effects alone. We calculate their FICI according to the protocol for investigating their 311 
synergistic relationships at preliminary level in this study [17,18]. For addressing the more 312 
complicated natural environment, the detailed concentration and structural relationship between 313 
peptides in this work needs a further and more systematic mechanism evaluation, which depends on 314 
the physiochemical parameters and their combination results of BHL-bombinin and bombinin HL, 315 
BHL-bombinin may have direct and selective membrane permeabilizing-activity, which increases the 316 
uptake of other antibacterial agents that initiate the process to interfere with intracellular targets or 317 
enhance the effect of highly hydrophobic molecules like bombinin HL. On the other hand, either 318 
bombinin HL or bombinin HD may cause degradation of the peptidoglycan by triggering the activity 319 
of bacterial murein hydrolases, which can enhance the activity of the β-lactams [28-30].  320 
Safety evaluations via haemolytic assay demonstrated the relatively lower SIs of both bombinin HL 321 
and bombinin HD on horse erythrocytes compared with BHL-bombinin, as a consequence, when 322 
treated HMEC-1 cells with the peptides using their MIC concentrations for MTT-based viability 323 
assessment, bomhinin HL and HD exhibited higher cytotoxicity. The typical theory is that the 324 
increased hydrophobicity of the AMPs is associated with higher antimicrobial activity, but in contrast, 325 
the high hydrophobic peptides are more associated with stronger self-assembly, which can result in 326 
the formation of dimers or oligomers. This spatial character may in turn decrease their potential for 327 
passing through the target cell wall and bacterial membrane [31]. The high toxicity of BHL-bombinin 328 
in this study might be mainly due to its innate character of highly hydrophobicity. Additionally, the 329 
abolishment of combined effect of BHL-bombinin and bombinin H against HMEC-1 revealed their 330 
high functional selectivity. The application of combined antimicrobial agents, either with AMPs or 331 
with conventional antibiotics, is a prospective strategy to improve clinical therapy caused by multi-332 
drug resistant pathogens and decrease the side-effect [32]. 333 
 334 
5. Conclusion  335 
In this project, the novel BHL-bombinin, bombinin HL and analogue bombinin HD are reported from 336 
less-studied frog species Bombina orientalis. They revealed comparable antimicrobial property 337 
individually and enhanced synergistic effect and selectivity jointly, all these inherent and robust 338 
characteristics hold significant potential to alleviate the current antibiotics crisis. 339 
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 448 
Figure legends and Tables 449 
Figure 1 The nucleotide sequence and open-reading frame amino acid sequence of full length preprobombinin 450 
and preprobombinin H peptides encoding cDNA from the oriental fire-bellied toad, Bombina orientalis. The 451 
putative signal peptide was double-underlined. The mature peptide was single-underlined for bombinin and 452 
dash-underlined for bombinin H. The stop codon was indicated by an asterisk. 453 
 454 
Figure 2 Alignment of the primary structure of the novel peptides BHL-Bombinin (a) and bombinin HL (b) with 455 
other bombinin family peptides. An * (asterisk) indicates positions that have a single, fully conserved residue. 456 
Substitutions are highlighted in grey. D-amino acids are boldfaced and italic. Gap residues are represented by 457 
dashes. a Sequences deduced from BLP-3 and BLP-7 genes, GH means gene-derived bombinin H-like peptide. 458 
 459 
Figure 3 Region of reverse phase HPLC chromatogram of Bombina orientalis skin secretion with arrow 460 
indicating the retention times of the novel BHL-Bombinin (1) and Bombinin HL (2). The detection wavelength 461 
was 214 nm with a flow rate of 1 ml/min in 240 min. 462 
 463 
Figure 4 Thermoquest LCQ™ fragment scan spectrum derived from ions corresponding to BHL-Bombinin (a) 464 
and electrospray ion-trap MS/MS fragmentation dataset (b). Expected single- and double-charged b- ions and y- 465 
ions arising from MS/MS fragmentation were predicted using the MS Product programme through Protein 466 
Prospector on-line. Truly observed ions are indicated in bold typeface and underlined.  467 
 468 
Figure 5 Thermoquest LCQ™ fragment scan spectrum derived from ions corresponding to Bombinin HL (a) 469 
and electrospray ion-trap MS/MS fragmentation dataset (b). Expected single- and double-charged b- ions and y- 470 
ions arising from MS/MS fragmentation were predicted using the MS Product programme through Protein 471 
Prospector on-line. Truly observed ions are indicated in bold typeface and underlined.  472 
 473 
Figure 6 Time-killing curves for combinational treatment of peptides and antimicrobial agents against S. aureus. 474 
Control (red circle/line), bombinin HL and bombinin HD (green square/line), ampicillin (brown triangle/line), 475 
BHL-Bombinin (purple triangle/line), combination pairs (black inverted triangle/line),  The detection limit is 476 
indicated as a dashed line. The graphs were derived from values of three independent trials. 477 
 478 
Figure 7 Cytotoxicity assessment of AMPs. Dose-dependent antiproliferative effects of BHL-Bombinin (a), 479 
bombinin HL and bombinin HD (b) against HMEC-1 after 24 h of incubation (V, N and P represent vehicle 480 
control, negative control and positive control respectively). The levels of significance are: * p < 0.05; ** p < 481 
0.01; *** p < 0.001 versus vehicle. The growth inhibition rate graphs of combination effects among a series 482 
concentration between BHL-bombinin with bombinin HL(c) or bombinin HD (d) against HMEC-1 after 483 
incubation for 24 h. (e) Combination index Q of the combination treatment of synergistic pairs, where Q < 0.85, 484 
Q > 1.15 and 0.85 < Q < 1.15 represent antagonism, synergy, and additive effect, respectively. (f) CI-effect plots 485 
were generated using CalcuSyn software. The points represent CI values for the combinations 5, 10, 20 µM 486 
BHL-bombinin with 10, 20, 40 µM bombinin HL or bombinin HD in a constant ratio against HMEC-1. 487 
 488 
Table 1 Physico-chemical characteristics of the novel AMPs BHL-Bombinin and Bombinin HL.  489 
 490 
Table 2 The susceptibility of novel AMPs and melittin peptide against microbial strains, bacterial biofilm and 491 
their selectivity indices (SIs) against S. aureus. a NA: not active; no inhibition or bactericidal activity was 492 
observed using peptide concentrations up to and including 512mg/L. b SI (selectivity index) defined as the ratio 493 
of HC50 to MIC against S. aureus value (HC50/MIC). When no or mild haemolysis was observed at the highest 494 
concentration employed (512 mg/l), a value of 1024 mg/l was used for calculation. 495 
 496 
Table 3 The combinational effects of the novel AMPs with ampicillin against S. aureus using checkerboard 497 
titration method. a The MIC values of Ampicillin is 0.0625 mg/l against S. aureus.  498 
 499 
 500 
 501 
 502 
 503 
 504 
 505 
 506 
Figure 1 507 
                 M  N  F   K  Y  I  V   A  V  S   F  L  I   A  S  A  Y 508 
            1   ATGAATTTTA AGTACATAGT TGCAGTGTCC TTTTTAATAG CATCTGCATA 509 
                TACTTAAAAT TCATGTATCA ACGTCACAGG AAAAATTATC GTAGACGTAT 510 
                  A  R  S   V  Q  N   D  E  Q  S   L  S  Q   R  D  V   511 
           51   TGCACGAAGT GTACAGAATG ATGAACAGTC TCTGAGTCAG AGGGATGTTT 512 
                ACGTGCTTCA CATGTCTTAC TACTTGTCAG AGACTCAGTC TCCCTACAAA 513 
                L  E  E  E   S  L  R   E  I  R   G  I  G  G   A  L  L 514 
          101   TAGAAGAAGA ATCACTGAGG GAAATCAGAG GTATAGGAGG AGCCCTCCTA 515 
                ATCTTCTTCT TAGTGACTCC CTTTAGTCTC CATATCCTCC TCGGGAGGAT 516 
                 S  F  G   K  S  A  L   K  G  L   A  K  G   L  A  E  H  517 
          151   AGTTTTGGTA AATCAGCTTT AAAAGGCTTG GCTAAAGGAT TGGCTGAGCA 518 
                TCAAAACCAT TTAGTCGAAA TTTTCCGAAC CGATTTCCTA ACCGACTCGT 519 
                  F  G  K   R  T  A   E  E  H  E   V  M  K   R  L  E   520 
          201   TTTTGGGAAG AGAACAGCTG AAGAACATGA AGTGATGAAA AGACTGGAAG 521 
                AAAACCCTTC TCTTGTCGAC TTCTTGTACT TCACTACTTT TCTGACCTTC 522 
                A  R  M  R   D  L  D   S  L  D   Y  P  E  E   A  S  E 523 
          251   CCAGAATGCG TGATCTAGAT TCCTTGGATT ATCCAGAGGA AGCTTCTGAA 524 
                GGTCTTACGC ACTAGATCTA AGGAACCTAA TAGGTCTCCT TCGAAGACTT 525 
                 R  E  T   R  S  F  N   Q  E  E   I  A  N   L  F  T  K 526 
          301   AGGGAAACCA GAAGCTTCAA TCAAGAGGAG ATTGCAAATC TTTTTACTAA 527 
                TCCCTTTGGT CTTCGAAGTT AGTTCTCCTC TAACGTTTAG AAAAATGATT 528 
                  K  E  K   R  L  L   G  P  V  L   G  L  V   S  N  V   529 
          351   AAAAGAGAAA CGCCTTTTGG GGCCAGTATT AGGTTTGGTT TCTAATGTAC 530 
                TTTTCTCTTT GCGGAAAACC CCGGTCATAA TCCAAACCAA AGATTACATG 531 
                L  G  G  L   L  G  * 532 
          401   TTGGAGGTTT ACTTGGATAA TTATAGCCAG TAAAACTTTG CTTTCATTAA 533 
                AACCTCCAAA TGAACCTATT AATATCGGTC ATTTTGAAAC GAAAGTAATT 534 
          451   GTCAGTAAAC TTGCTTCATT ATGTTGTAAA TGAGCTATCA GATACATATA 535 
                CAGTCATTTG AACGAAGTAA TACAACATTT ACTCGATAGT CTATGTATAT 536 
          501   TAAGCATAGA TAAACACACA CAAAGTATTA ACAACTGCTG TCTGTACTCT 537 
                ATTCGTATCT ATTTGTGTGT GTTTCATAAT TGTTGACGAC AGACATGAGA 538 
          551   GCTTTAATAA AATCGATGAC AAAAAAAAAA AAAAAAAA 539 
               CGAAATTATT TTAGCTACTG TTTTTTTTTT TTTTTTTT 540 
 541 
 542 
Figure 2 543 
BHL-Bombinin    GIGGALLSFGKSALKGLAKGLAEHF---NH2 
Bombinin-like peptides BLP-3a                                  GIGAAILSAGKSALKGLAKGLAEHF---NH2 
Bombinin-like peptides BLP-7a                                  GIGGALLSAGKSALKGLAKGLAEHFAN-NH2    
FPA-bombinin-BO                        GIGGALLSAGKAALKGLAKGLAEHFAN-NH2      
FPA-bombinin-BV                        GIGGALLNVGKVALKGLAKGLAEHFAN-NH2               
Maximin-4                              GIGGVLLSAGKAALKGLAKVLAEKYAN-NH2 
 ***  **  ** ***********     
(a) 544 
 545 
Bombinin HL LLGPVLGLVSNVLGGLL----NH2 
Bombinin HVD LLGPVLGLVSNVLGGLL----NH2 
Bombinin H6                                     ILGPILGLVSNALGGLL----NH2  
Bombinin H7                                     ILGPILGLVSNALGGLL----NH2  
Bombinin H2                                     IIGPVLGLVGSALGGLLKKI-NH2 
Bombinin H4                                     IIGPVLGLVGSALGGLLKKI-NH2                     
Bombinin GH-1La                                  IIGPVLGLVGKPLESLLE---NH2   
Bombinin GH-1Da                                  IIGPVLGLVGKPLESLLE---NH2  
   ** ****   *  ** 
(b) 546 
Figure 3  547 
 548 
 549 
 550 
 551 
Figure 4 552 
 553 
(a) 554 
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2 
1 58.03 29.52 G     25 
2 171.11 86.06 I 2384.38 1192.69 24 
3 228.13 114.57 G 2271.30 1136.15 23 
4 285.16 143.08 G 2214.28 1107.64 22 
5 356.19 178.60 A 2157.25 1079.13 21 
6 469.28 235.14 L 2086.22 1043.61 20 
7 582.36 291.68 L 1973.13 987.07 19 
8 669.39 335.20 S 1860.05 930.53 18 
9 816.46 408.73 F 1773.02 887.01 17 
10 873.48 437.25 G 1625.95 813.48 16 
11 1001.58 501.29 K 1568.93 784.97 15 
12 1088.61 544.81 S 1440.83 720.92 14 
13 1159.65 580.33 A 1353.80 677.40 13 
14 1272.73 636.87 L 1282.76 641.89 12 
15 1400.83 700.92 K 1169.68 585.34 11 
16 1457.85 729.43 G 1041.58 521.30 10 
17 1570.93 785.97 L 984.56 492.78 9 
18 1641.97 821.49 A 871.48 436.24 8 
19 1770.06 885.54 K 800.44 400.72 7 
20 1827.09 914.05 G 672.35 336.68 6 
21 1940.17 970.59 L 615.32 308.17 5 
22 2011.21 1006.11 A 502.24 251.62 4 
23 2140.25 1070.63 E 431.20 216.11 3 
24 2277.31 1139.16 H 302.16 151.58 2 
25     F-Amidated 165.10 83.05 1 
 555 
(b) 556 
 557 
 558 
Figure 5 559 
 560 
(a) 561 
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2 
1 114.09 57.55 L   17 
2 227.18 114.09 L 1519.96 760.48 16 
3 284.20 142.60 G 1406.87 703.94 15 
4 381.25 191.13 P 1349.85 675.43 14 
5 480.32 240.66 V 1252.80 626.90 13 
6 593.40 297.20 L 1153.73 577.37 12 
7 650.42 325.72 G 1040.65 520.83 11 
8 763.51 382.26 L 983.62 492.32 10 
9 862.58 431.79 V 870.54 435.77 9 
10 949.61 475.31 S 771.47 386.24 8 
11 1063.65 532.33 N 684.44 342.72 7 
12 1162.72 581.86 V 570.40 285.70 6 
13 1275.80 638.41 L 471.33 236.17 5 
14 1332.83 666.92 G 358.24 179.63 4 
15 1389.85 695.43 G 301.22 151.12 3 
16 1502.93 751.97 L 244.20 122.60 2 
17     L-Amidated 131.12 66.06 1 
 562 
(b) 563 
 564 
 565 
 566 
 567 
 568 
Figure 6 569 
           570 
                                            (a)                                                                                                                             (b) 571 
             572 
                                              (c)                                                                                                                              (d) 573 
 574 
Figure 7 575 
                    576 
 577 
                                                   (a)                                                                                                                         (b) 578 
 BHL-Bombinin Bombinin HL Bombinin HD 
IC50(µM) 94.32±0.72 103.51±0.43 104.23±0.24 
 579 
 580 
 581 
                    582 
 583 
                                               (c)                                                                                                                      (d) 584 
                       585 
                                             (e)                                                                                                                           (f)                          586 
 587 
Table 1 588 
Peptides Theoretical Mw 
Measure
d Mw 
Hydrophobicity 
(H) 
Hydrophobic 
moment (µH) 
Net 
charge %Helicity 
BHL-Bombinin 2441.87 2441.50 0.462 0.404 +3 87.59 
Bombinin HL 1633.03 1633.02 0.920 0.501 +1 77.73 
 589 
 590 
Table 2 591 
Peptides 
MIC / MBC [mg/l(µM)] MIC / MFC [mg/l(µM)] 
MBEC 
 [mg/L(µM)] HC50 
[mg/l(µM)] SI
b Gram-positive bacteria Gram-negative bacteria Fungi 
S. aureus S. aureus MRSA E. coli P. aeruginosa C. albicans 
BHL-Bombinin 4(1.6)/ 16(6.6) 16(6.6)/ 64(26.2) 
16(6.6)/ 
64(26.2) 
64(26.2)/ 
128(52.4) 
4(1.6)/ 
16(16.6) 4(1.6) 64(26.2) 16 
Bombinin HL 256(156.8)/ NAa NA/ NA NA/ NA NA/ NA NA/ NA NA ˃512(313.5) 4 
Bombinin HD 128(78.4)/ NA NA/ NA NA/ NA NA/ NA NA/ NA NA ˃512(313.5) 8 
Melittin 8(2.8)/16(5.6) 32(11.2)/ 64(22.4) 
16(5.6)/ 
32(11.2) 
16(5.6)/ 
64(22.4) 
8(2.8)/ 
16(5.6) 8(2.8) 1(0.4) 0.125 
 592 
 593 
 594 
 595 
Table 3 596 
The antimicrobial treatment settings Lowest FIC index 
([A]/[B] in mg/l) Results A B 
BHL-Bombinin Bombinin HL 0.375(0.75/48) Synergistic Bombinin HD 0.375(0.75/24) Synergistic 
             Ampicillina 0.75(2/ 0.016) Additive 
Bombinin HL Ampicillin 0.5(64/0.016) Synergistic 
 597 
  598 
Bombinin HD Ampicillin 0.5(32/0.016) Synergistic 
Supplementary data 599 
 600 
(a) 601 
 602 
 603 
(b) 604 
 605 
(c) 606 
Figure S1 MALDI-TOF (Perceptive Biosystem, Bedford, MA, USA) mass spectrum of synthetic peptide (a) bombinin HL and (b) bombinin HD and (c) 607 
BHL-bombinin. In (b), the initial neutral molecule bombinin HD [M] and metal ion adducts ([M+Na]+: 1654.35Da and [M+K]+: 1669.70Da) were observed.  608 
                                                           609 
 610 
 611 
Figure S2   CD spectra of the peptides in 10 mM ammonium acetate buffer (triangles) and 50% TFE (circles). The mean residue ellipticity was plotted 612 
against wavelength. The values from three scans were calculated as average per sample. The peptide concentrations were fixed at 100 μM. 613 
 614 
 615 
Figure S3   Haemolytic activities of BHL-bombinin (diamond), bombinin HL (square), bombinin HD (triangle) and melittin (cross) following incubation with 616 
horse erythrocytes for 2 h. 617 
 618 
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Figure S4 Time-killing curves of peptides and ampicillin at a series of concentrations: control (red filled circle), 0.25×MIC (red unfilled circle), 0.5×MIC 633 
(green diamond), 1×MIC (blue inverted triagle), 2×MIC (purple triagle) and 4×MIC (black square) against A: S.aureus [(a) BHL-bombinin (b) bombinin HL 634 
(c) bombinin HD (d) ampicillin]; B: E.coli [(e) BHL-bombinin (f) ampicillin]; C: C.albicans [(g) BHL-bombinin]. The detection limit was indicated as 635 
dashed line and the graphs were derived value of three independent trials. 636 
